<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="504">
  <stage>Registered</stage>
  <submitdate>7/12/2004</submitdate>
  <approvaldate>7/12/2004</approvaldate>
  <nctid>NCT00098683</nctid>
  <trial_identification>
    <studytitle>Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes</studytitle>
    <scientifictitle>A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CDR0000398140</secondaryid>
    <secondaryid>AAML0121</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Myelodysplastic/Myeloproliferative Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - amifostine trihydrate

Treatment: drugs: amifostine trihydrate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hematological effects (complete and partial response)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety and efficacy</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of progression-free remission</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of karyotypic abnormalities on survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of the number of cytopenias on survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation of the duration of time from diagnosis of myelodysplastic syndromes until conversion to acute myeloid leukemia</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of myelodysplastic syndromes (MDS)

               -  One of the following subtypes:

                    -  Refractory anemia (RA)

                    -  RA with ringed sideroblasts

                    -  RA with excess blasts

                    -  Refractory cytopenia with multilineage dysplasia (RCMD)

                    -  RCMD and ringed sideroblasts

                    -  MDS, unclassified

                    -  MDS associated with isolated del 5(q)

          -  De novo disease

               -  No treatment-induced MDS

          -  No juvenile myelomonocytic leukemia

          -  No Down syndrome, Fanconi's anemia, or other inherited forms of hypoplastic bone
             marrow failure

        PATIENT CHARACTERISTICS:

        Age

          -  1 to 21 at original diagnosis

        Performance status

          -  Karnofsky 50-100% (patients &gt; 16 years of age)

          -  Lansky 50-100% (patients 1 to 16 years of age)

        Life expectancy

          -  At least 8 weeks

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin = 1.5 times upper limit of normal (ULN)

          -  ALT &lt; 2.5 times ULN

        Renal

          -  Radioisotope glomerular filtration rate = 60 mL/min OR

          -  Creatinine clearance &gt; 60 mL/min (based on Schwartz formula)

          -  Calcium normal

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Serum electrolytes normal

          -  Phosphorus normal

          -  Magnesium normal

          -  Glucose normal

          -  No other concurrent malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 8 weeks since prior growth factors

          -  No concurrent growth factors

          -  No concurrent hematopoietic stem cell transplantation

          -  No concurrent immunomodulating agents

        Chemotherapy

          -  No prior amifostine

          -  No other concurrent anticancer chemotherapy

        Endocrine therapy

          -  No concurrent daily steroid therapy

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No prior therapy for MDS</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Santurce</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy, such as amifostine, work in different ways to stop the
      growth of cancer cells, either by killing the cells or by stopping them from dividing.

      PURPOSE: This phase II trial is studying how well amifostine works in treating young patients
      with newly diagnosed de novo myelodysplastic syndromes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00098683</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prasad Mathew, MD</name>
      <address>University of New Mexico Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>